NKX3.1 versus cyclin D1 expression in prostatic adenocarcinoma: a comparative study

Conclusion NKX3.1 antibody can be used for early detection of the PAC and treatment must be focused more on NKX3.1 than cyclin D1 inhibitors.
Source: Egyptian Journal of Pathology - Category: Pathology Tags: Original Articles Source Type: research